Industry

Iantrek introduces AlloSpan Canal bio-interventional platform

Healio Optometry5h ago1 min read

Iantrek announced controlled early clinical adoption of the AlloSpan Canal at select U.S. sites.The canal-based restoration platform combines a trabecular meshwork-sparing, nitinol-guided canaloplasty with the placement of a scleral bio-implant, which reinforces the structure of the canal in patients with glaucoma, according to a press release.{{VIDEO}}Sean Ianchulev, MD, MPH, founder of Iantrek, will feature the AlloSpan Canal technology during the Charles D. Kelman, MD, Innovator’s Lecture at the American Society of Cataract and Refractive Surgery meeting in Washington.Iantrek will use

Read full article on Healio Optometry

AI Summary

Quick Take

Iantrek has initiated the controlled early clinical adoption of its AlloSpan Canal platform, a bio-interventional system designed to restore aqueous outflow in glaucoma patients. The technology combines a nitinol-guided, trabecular meshwork-sparing canaloplasty with a scleral bio-implant that provides structural reinforcement to Schlemm’s canal.

Why It Matters

The move toward 'bio-interventional' glaucoma surgery represents a significant pivot from traditional synthetic micro-stents toward using natural tissue-based materials for canal stabilization. By sparing the trabecular meshwork and reinforcing the canal's natural architecture, this platform aims to achieve physiological pressure reduction with potentially fewer long-term foreign body complications. Given that the technology is being championed by Dr. Sean Ianchulev—a key figure in ophthalmic innovation—its clinical performance will be closely watched by the surgical community.

Key Details

The AlloSpan Canal platform utilizes a nitinol-guided delivery system to perform canaloplasty while sparing the trabecular meshwork.
The system incorporates a scleral bio-implant specifically designed to reinforce the structural integrity of Schlemm’s canal.
The technology is currently in a controlled early clinical adoption phase at select surgical sites across the United States.
Founder Sean Ianchulev, MD, MPH, will present the technology during the prestigious Charles D. Kelman, MD, Innovator’s Lecture at the ASCRS meeting.
The approach focuses on canal-based restoration rather than bypass, aiming to maintain the eye's natural drainage pathways.

Practice Implications

Glaucoma specialists and cataract surgeons should evaluate how bio-implants might fit into their MIGS armamentarium, particularly for patients where preserving the trabecular meshwork is a clinical priority. As the platform enters early adoption, clinicians should look for data regarding the long-term patency of the canal and the stability of the bio-implant compared to traditional metallic or polymer stents.

Who's Affected

Glaucoma SpecialistsCataract SurgeonsOphthalmic SurgeonsPractice Owners

What's Next

Following the initial rollout at select U.S. sites, further clinical data is expected to be shared during major industry meetings like ASCRS. The medical community will be looking for long-term safety and efficacy results to determine if this bio-interventional approach will become a standard alternative to traditional micro-invasive glaucoma surgeries.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.